KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Goodwill & Intangibles (2016 - 2024)

Historic Goodwill & Intangibles for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q1 2024 value amounting to $2000.0.

  • CRISPR Therapeutics AG's Goodwill & Intangibles fell 9649.12% to $2000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $2000.0, marking a year-over-year decrease of 9649.12%. This contributed to the annual value of $16000.0 for FY2023, which is 7746.48% down from last year.
  • According to the latest figures from Q1 2024, CRISPR Therapeutics AG's Goodwill & Intangibles is $2000.0, which was down 9649.12% from $16000.0 recorded in Q4 2023.
  • In the past 5 years, CRISPR Therapeutics AG's Goodwill & Intangibles ranged from a high of $221000.0 in Q1 2020 and a low of $2000.0 during Q1 2024
  • Its 5-year average for Goodwill & Intangibles is $111764.7, with a median of $112000.0 in 2022.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Goodwill & Intangibles plummeted by 1992.75% in 2020 and then crashed by 9649.12% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Goodwill & Intangibles (Quarter) stood at $180000.0 in 2020, then tumbled by 30.56% to $125000.0 in 2021, then crashed by 43.2% to $71000.0 in 2022, then crashed by 77.46% to $16000.0 in 2023, then tumbled by 87.5% to $2000.0 in 2024.
  • Its last three reported values are $2000.0 in Q1 2024, $16000.0 for Q4 2023, and $30000.0 during Q3 2023.